Nutex Health (NUTX) 8-K NUTEX HEALTH Inc. reports fourth quarter and Full YEAR 2022 financial results

Exhibit 99.2

Supplemental Financial Disclosures

Revised Consolidated Balance Sheets

	June 30, 2022
		As				As
		Reported		Revisions		Revised
Revised balance sheet information
Total current assets	$	148,980,554	$	-	$	148,980,554
Goodwill		425,355,837		(10,331,537)		415,024,300
Other long-term assets		297,456,869		-		297,456,869
Total assets	$	871,793,260	$	(10,331,537)	$	861,461,723
Total liabilities	$	305,379,017	$	-	$	305,379,017
Equity:
Common stock		648,918		-		648,918
Additional paid-in capital		467,402,221		(10,331,537)		457,070,684
Retained earnings		63,550,536		-		63,550,536
Nutex Health Inc. equity		531,601,675		(10,331,537)		521,270,138
Noncontrolling interests		34,812,568		-		34,812,568
Total equity		566,414,243		(10,331,537)		556,082,706
Total liabilities and equity	$	871,793,260	$	(10,331,537)	$	861,461,723
	September 30, 2022
		As				As
		Reported		Revisions		Revised
Revised balance sheet information
Equity:
Common stock	$	649,770	$	-	$	649,770
Additional paid-in capital		468,802,618		(10,331,537)		458,471,081
Retained earnings (accumulated deficit)		(358,967,267)		10,331,537		(348,635,730)
Nutex Health Inc. equity		110,485,121		-		110,485,121
Noncontrolling interests		22,042,881		-		22,042,881
Total equity	$	132,528,002	$	-	$	132,528,002

Revised Consolidated Statements of Operations

	Three Months Ended September 30, 2022
		As				As
		Reported		Revisions		Revised
Revised statements of operations information
Revenue	$	28,395,058	$	-	$	28,395,058
Operating costs and expenses		54,863,504		-		54,863,504
Impairment of goodwill		408,466,575		(10,331,537)		398,135,038
General and administrative expenses		4,077,255		-		4,077,255
Operating income		(439,012,276)		10,331,537		(428,680,739)
Interest expense		3,402,606		-		3,402,606
Other expense (income)		(630,450)		-		(630,450)
Income tax expense		(8,543,880)		-		(8,543,880)
Net income (loss)		(433,240,552)		10,331,537		(422,909,015)
Net income (loss) attributable to noncontrolling interests		(10,722,749)		-		(10,722,749)
Net income (loss) attributable to Nutex	$	(422,517,803)	$	10,331,537	$	(412,186,266)
	Nine Months Ended September 30, 2022
		As				As
		Reported		Revisions		Revised
Revised statements of operations information
Revenue	$	165,570,233	$	-	$	165,570,233
Operating costs and expenses		152,648,175		-		152,648,175
Acquisition costs		3,885,666		-		3,885,666
Impairment of goodwill		408,466,575		(10,331,537)		398,135,038
General and administrative expenses		11,721,597		-		11,721,597
Operating income		(411,151,780)		10,331,537		(400,820,243)
Interest expense		9,628,189		-		9,628,189
Other expense (income)		346,873		-		346,873
Income tax expense		11,285,729		-		11,285,729
Net income (loss)		(432,412,571)		10,331,537		(422,081,034)
Net income (loss) attributable to noncontrolling interests		(12,052,765)		-		(12,052,765)
Net income (loss) attributable to Nutex	$	(420,359,806)	$	10,331,537	$	(410,028,269)

Revised Consolidated Statements of Changes in Equity

	Three months ended June 30, 2022
		As				As
		Reported		Revisions		Revised
Revised statements of changes in equity information
Reverse acquisition with Clinigence
Common stock	$	50,961	$	-	$	50,961
Additional paid-in capital		446,780,842		(10,331,537)		436,449,305
Noncontrolling interest		194,747		-		194,747
Total reverse acquisition with Clinigence	$	447,026,550	$	(10,331,537)	$	436,695,013
	Three months ended September 30, 2022
		As				As
		Reported		Revisions		Revised
Revised statements of changes in equity information
Balance at June 30, 2022
Common stock	$	648,918	$	-	$	648,918
Additional paid-in capital		467,402,221		(10,331,537)		457,070,684
Retained earnings		63,550,536		-		63,550,536
Noncontrolling interest		34,812,568		-		34,812,568
Total balance at June 30, 2022	$	566,414,243	$	(10,331,537)	$	556,082,706
Net income (loss)
Retained earnings	$	(422,517,803)	$	10,331,537	$	(412,186,266)
Noncontrolling interest		(10,722,749)		-		(10,722,749)
Total net income (loss)	$	(433,240,552)	$	10,331,537	$	(422,909,015)

Revised Consolidated Statement of Cash Flows

	Nine months ended September 30, 2022
		As			��		As
		Reported		Revisions			Revised
Revised statement of cash flows
Net income (loss)	$	(432,412,571)	$	10,331,537		$	(422,081,034)
Impairment of goodwill		408,466,575		(10,331,537)			398,135,038
Net cash from operating activities		46,101,114		-			46,101,114